Hepatitis C virus infection enhances TNFα‐induced cell death via suppression of NF‐κB

Junseong Park, Wonseok Kang, Seung‐Wook Ryu, Woo‐Il Kim, Dong‐Yeop Chang, Dong Ho Lee, Do Youn Park, Youn‐Hee Choi, Kyungsun Choi, Eui‐Cheol Shin, Chulhee Choi – 20 March 2012 – Hepatitis C virus (HCV) infection results in liver injury and long‐term complications, such as liver cirrhosis and hepatocellular carcinoma. Liver injury in HCV infection is believed to be caused by host immune responses, not by viral cytopathic effects. Tumor necrosis factor‐alpha (TNF‐α) plays a pivotal role in the inflammatory processes of hepatitis C.

Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial

Thuy‐Anh Le, Joshua Chen, Christopher Changchien, Michael R. Peterson, Yuko Kono, Heather Patton, Benjamin L. Cohen, David Brenner, Claude Sirlin, Rohit Loomba, for the San Diego Integrated NAFLD Research Consortium (SINC) – 20 March 2012 – Bile acid sequestrants (BAS) lower plasma low density lipoprotein levels and improve glycemic control. Colestimide, a BAS, has been claimed by computed tomography to reduce liver fat. Therefore, we examined the efficacy of colesevelam, a potent BAS, to decrease liver fat in patients with biopsy‐proven nonalcoholic steatohepatitis (NASH).

Prevention of de novo hepatitis B with adefovir dipivoxil in recipients of liver grafts from hepatitis B core antibody–positive donors

Matthew S. Chang, Sonja K. Olsen, Elsa M. Pichardo, Scott Heese, Jessica B. Stiles, Rita Abdelmessih, Elizabeth C. Verna, James V. Guarrera, Jean C. Emond, Robert S. Brown – 16 March 2012 – Lamivudine has been shown to prevent de novo hepatitis B virus (HBV) infections in liver transplantation (LT) patients receiving hepatitis B core antibody–positive (HBcAb+) grafts, but it may produce long‐term resistance. Adefovir dipivoxil (ADV) might be effective in preventing de novo hepatitis and resistance.

Immediate intraportal transplantation of human bone marrow mesenchymal stem cells prevents death from fulminant hepatic failure in pigs

Jun Li, Liyuan Zhang, Jiaojiao Xin, Longyan Jiang, Jun Li, Ting Zhang, Linfeng Jin, Jianzhou Li, Pengcheng Zhou, Shaorui Hao, Hongcui Cao, Lanjuan Li – 16 March 2012 – The effectiveness of human bone marrow mesenchymal stem cell (hBMSC) transplantation to treat acute and chronic liver injury has been demonstrated in animal models and in a few nonrandomized clinical trials. However, no studies have investigated hBMSC transplantation in the treatment of fulminant hepatic failure (FHF), especially in large animal (pig) models.

Subscribe to